CATALOGO DEI PRODOTTI DELLA RICERCA

FRACASSO, Giulio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.546
EU - Europa 3.196
AS - Asia 1.662
SA - Sud America 54
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 3
Totale 8.476
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.498
GB - Regno Unito 1.180
CN - Cina 964
SG - Singapore 461
IT - Italia 323
SE - Svezia 304
IE - Irlanda 292
FR - Francia 272
RU - Federazione Russa 252
FI - Finlandia 207
DE - Germania 187
UA - Ucraina 71
VN - Vietnam 52
KR - Corea 36
BR - Brasile 35
CA - Canada 34
TR - Turchia 31
BE - Belgio 29
ID - Indonesia 25
IR - Iran 20
JP - Giappone 18
PL - Polonia 16
IN - India 13
MX - Messico 11
NL - Olanda 10
EC - Ecuador 7
CH - Svizzera 6
ES - Italia 6
HK - Hong Kong 6
AR - Argentina 5
PH - Filippine 5
PT - Portogallo 5
BD - Bangladesh 4
LV - Lettonia 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
AZ - Azerbaigian 3
BY - Bielorussia 3
CL - Cile 3
DK - Danimarca 3
EU - Europa 3
GR - Grecia 3
HR - Croazia 3
KW - Kuwait 3
LU - Lussemburgo 3
TG - Togo 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CM - Camerun 2
CZ - Repubblica Ceca 2
EG - Egitto 2
LT - Lituania 2
MA - Marocco 2
NO - Norvegia 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
UZ - Uzbekistan 2
AL - Albania 1
AT - Austria 1
BG - Bulgaria 1
BO - Bolivia 1
BT - Bhutan 1
BW - Botswana 1
CY - Cipro 1
HN - Honduras 1
HU - Ungheria 1
IM - Isola di Man 1
IQ - Iraq 1
JM - Giamaica 1
JO - Giordania 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
ME - Montenegro 1
PA - Panama 1
PE - Perù 1
PK - Pakistan 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
TJ - Tagikistan 1
UY - Uruguay 1
VE - Venezuela 1
Totale 8.476
Salva come PNG Salva come JPEG
Città #
Southend 1.073
Chandler 644
Jacksonville 563
Woodbridge 408
Singapore 374
Dublin 289
Ann Arbor 281
Houston 203
Ashburn 188
Beijing 181
Verona 134
Lawrence 106
Princeton 106
Wilmington 100
Jinan 91
Nanjing 76
Shenyang 64
Helsinki 56
New York 52
Hebei 49
Tianjin 47
Changsha 41
Sindelfingen 39
Dong Ket 35
Zhengzhou 35
Seoul 31
Brussels 29
Boardman 28
Seattle 26
Haikou 25
Milan 25
Ningbo 25
Guangzhou 23
Redwood City 23
Hangzhou 22
Jiaxing 22
Taizhou 22
Jakarta 21
Taiyuan 21
Nanchang 19
Norwalk 18
Lancaster 17
Fuzhou 16
Tokyo 16
Los Angeles 14
Redmond 14
Montréal 13
Santa Clara 13
Warsaw 13
Moscow 12
San Francisco 12
Bologna 11
Dallas 10
Falkenstein 9
Padova 9
Paris 8
Tehran 8
Kent 7
Lanzhou 7
Phoenix 7
Elora 5
Guayaquil 5
Salt Lake City 5
Toronto 5
Washington 5
Auburn Hills 4
Chicago 4
Dongguan 4
Fairfield 4
Frankfurt am Main 4
Kemerovo 4
Leawood 4
London 4
Riese Pio X 4
San Jose 4
Shanghai 4
Tappahannock 4
Amsterdam 3
Ardabil 3
Baku 3
Belluno 3
Cambridge 3
Chions 3
Dearborn 3
Düsseldorf 3
Edinburgh 3
Falls Church 3
Kochi 3
Lomé 3
Luxembourg 3
Lviv 3
Menlo Park 3
Montreal 3
Mumbai 3
Ome 3
Puxian 3
Riga 3
Rio de Janeiro 3
Salerno 3
Sejong 3
Totale 5.973
Salva come PNG Salva come JPEG
Nome #
Feasibility of telomerase-specific adoptive T-cell therapy for B-cell chronic lymphocytic leukemia and solid malignancies 130
Anti PSMA immunotoxins activity against prostate cancer cell lines. 128
Immunotoxins and other conjugates: preparation and general characteristics. 121
Filamin A-mediated interaction of Prostate Specific Membrane Antigen (PSMA) with beta1 integrin regulates survival of advanced prostate cancer cells 120
Cooperation of Prostate Specific Membrane Antigen with beta 1 integrin promotes the survival of aggressive prostate cancer cells 120
Targeted Killing of Prostate Cancer Cells using Antibody-Drug conjugated Carbon Nanohorns 120
Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo" 119
Anti-PSMA-Immunotoxins: a new therapeutical strategy for selective targeting of toxins to prostate cancer cells. 112
Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. 112
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumor cells by activating the MAPK pathways. 112
Anti PSCA Monoclonal Antibody and scFv-Fragment for Immunotherapy of Prostate, Pancreatic and Bladder Carcinoma 111
The prostate specific membrane antigen regulates the expression of IL-6 and CCL-5 in prostate tumour cells by activating the MAPK pathways 110
N-terminal deletion affetcs catalytic activity of saporin toxin. 109
Produzione e validazione preclinica di un anticorpo anti-PSMA per diagnostica ed immunotargeting 109
A SERRS/MRI multimodal contrast agent based on naked Au nanoparticles functionalized with a Gd(iii) loaded PEG polymer for tumor imaging and localized hyperthermia 108
Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing. 105
Investigation of Properties of Anti-Prostate Specific Membrane Antigen-targeted Gold Nanoparticles as Drug Carriers in Tumor Therapy 105
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer 105
Reductive activation of ricin and ricin-A chain immunotoxins by Protein Disulfide Isomerase and Thioredoxin Reductase system. 104
Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi 104
Plasmonic Nanostructures for SERRS Multiplexed Identification of Tumor-Associated Antigens 104
Protein Disulfide Isomerase and Thioredoxin Reductase: a ricin disulfide reducing system in the endoplasmic reticulum. 103
Production of a biotinylated anti-PSMA single-chain antibody fragment (scFv) for imaging and radioimmunotherapy 103
EpCAM a possible target for immunotoxin treatments of PSMA positive and negative prostate cancer cells 103
Characterization of a new anti PSCA monoclonal antibody and scFv fragment for diagnosis and immunotherapy of prostate, pancreatic and bladder carcinoma. 103
Targeted delivery of photosensitizers: efficacy and selectivity issues revealed by multifunctional ORMOSIL nanovectors in cellular systems 103
Ingegnerizzazione di un vettore per espressione di frammenti anticorpali (scFv) biotinilati in procarioti, purificazione ed analisi funzionale 102
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 100
Constitutive activation of p38 and ERK1/2 MAPKs in epithelial cells of myasthenic thymus leads to IL-6 and RANTES overexpression: effects on survival and migration of peripheral T and B cells. 96
Reductive activation of ricin and ricin A-chain immunotoxins by protein disulfide isomerase and thioredoxin reductase. 95
Prostate-specific membrane antigen associates already in the endoplasmic reticulum with lipid microdomains 95
A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin 94
Biodistribution of In-111-labeled D2B IgG, F(ab’)2 and Fab fragments in nude mice bearing human prostate cancer xenografts 94
Parallel optical read-out of micromechanical pillars applied to prostate specific membrane antigen detection 93
Anti-prostate specific membrane antigen targeted gold nanoparticles in tumor therapy and diagnosis 93
Tumor Targeting with Guided Silica Nanopartilces for Prostate Cancer Therapy 93
Top-down synthesis of multifunctional iron oxide nanoparticles for macrophage labelling and manipulation 92
Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof 91
Discriminatory role of detergent-resistant membranes in the dimerization and endocytosis of prostate-specific membrane antigen 91
Effect of therapeutic macromolecules in spheroids 90
Prostate-specific membrane antigen (PSMA) associates early in the endoplasmic reticulum with lipid microdomains 89
Targeting human prostate cancer with (111) In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts. 88
Generazione di nuovi anticorpi anti prostate stem cell antigen (PSCA) e loro caratterizzazione al fine di un futuro utilizzo nella terapia e nella diagnosi dei carcinomi prostatico, pancreatico e della vescica 87
Self-potentiation of ligand-toxin conjugates containing ricin A chain fused with viral structures 87
Expression of myelin basic protein (MBP) epitopes in human non-neural cells revealed by two anti-MBP IgM monoclonal antibodies 85
Identification of Ricin A chain HLA II-restricted epitopes by human T-cell clones. 84
Gangliosides act as onconeural antigens in paraneoplastic neuropathies. 83
Highly sensitive electrochemiluminescence detection of a prostate cancer biomarker 82
Prostate Specific Membrane Antigen (PSMA) associates with Filamin A, beta1 integrin, pp130CAS and pSrc thus regulating the activation of beta1 integrin and the survival of prostate cancer cells. 81
Magneto-Plasmonic Au-Fe alloy nanoparticles designed for multimodal SERS-MRI-CT imaging 80
The Filamin A-mediated cooperation of Prostate Specific Membrane Antigen (PSMA) with beta1 integrin promotes the survival of aggressive prostate cancer cells. 80
Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells 80
Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin 79
Pegylated silica nanoparticles: cytotoxicity and macrophage uptake 79
Cloning and characterisation of canine prostate-specific membrane antigen 78
Laser generated gold nanocorals with broadband plasmon absorption for photothermal applications 78
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models 77
An electrochemiluminescent-supramolecular approach to sarcosine detection for early diagnosis of prostate cancer. 77
Pharmacokinetics of intrathecal transferrin-ricin A chain immunotoxins 76
Therapeutic Efficacy of the Novel Stimuli-Sensitive Nano-Ferritins Containing Doxorubicin in a Head and Neck Cancer Model 74
Characterization of an In-111-labeled anti-PSMA antibody-photosensitizer conjugate for targeted photodynamic therapy of PSMA-expressing tumors 74
SERS IMAGING OF CANCER CELLS WITH ANTIBODY FUNCTIONALIZED GOLD NANOPARTICLES 73
Prostate-specific membrane antigen routing to the cell surface implicates an early association step in the endoplasmic reticulum with lipid microdomains. 71
Improved method for carbohydrate-deficient transferrin determination in human serum by capillary zone electrophoresis 71
In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe 71
Acute sarcomeric M-Line Disease associated with ATP synthase subunit α autoantibodies in ankylosing spondylitis 71
null 70
Targeted Silica Nanoparticles for PhotoDynamic Therapy (PDT) 68
Design and Evaluation of 223Ra-Labeled and Anti-{PSMA} Targeted {NaA} Nanozeolites for Prostate Cancer Therapy{ extendash}Part I 68
Characterization of In-111-labeled site-specifically conjugated anti-PSMA antibody-drug conjugates for treatment of PSMA-expressing tumors 67
SERS labels for quantitative assays: application to the quantification of gold nanoparticles uptaken by macrophage cells 66
Design and Evaluation of 223Ra-Labeled and Anti-{PSMA} Targeted {NaA} Nanozeolites for Prostate Cancer Therapy{ extemdash}Part {II}. Toxicity, Pharmacokinetics and Biodistribution 65
Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA) 64
Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer 64
Different Glycoforms of Prostate-Specific Membrane Antigen are intracellularly transported through their Association with Distinct Detergent-Resistant Membranes 62
null 61
Efficient AuFeOx Nanoclusters of Laser-Ablated Nanoparticles in Water for Cells Guiding and Surface-Enhanced Resonance Raman Scattering Imaging 61
Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors 61
Improved doxorubicin encapsulation and pharmacokinetics of ferritin-fusion protein nanocarriers bearing proline, serine, and alanine elements 59
The presence of glutamate residues on the PAS sequence of the stimuli-sensitive nano-ferritin improves in vivo biodistribution and mitoxantrone encapsulation homogeneity 58
Polymer-coated silver-iron nanoparticles as efficient and biodegradable MRI contrast agents 58
Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen 57
Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness 57
Mitoxantrone-loaded nanoferritin slows tumor growth and improves the overall survival rate in a subcutaneous pancreatic cancer mouse model 57
Safe Core-Satellite Magneto-Plasmonic Nanostructures for Efficient Targeting and Photothermal Treatment of Tumor Cells 56
Simple and Rapid Non-Enzymatic Procedure Allows the Isolation of Structurally Preserved Connective Tissue Micro-Fragments Enriched with SVF 56
Ribosome-inactivating protein-containing conjugates for therapeutic use 55
New Tc-99m-radioimmunoconjugates for pancreatic carcinoma detection 55
SERRS Multiplexing with Multivalent Nanostructures for the Identification and Enumeration of Epithelial and Mesenchymal Cells 54
Immunology of RIPs and their Immunotoxins, in Ribosome-inactivating Proteins: Ricin and Related Proteins 53
Neutralization of NET-associated human ARG1 enhances cancer immunotherapy 52
Engineered Human Nanoferritin Bearing the Drug Genz-644282 for Cancer Therapy 51
D2B antibody and its scFvD2B fragment in nanomedicine: promising tools in the theranostics of prostate cancer 51
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma 50
High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors 50
Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones 49
Dual modality imaging of PSMA-expressing prostate cancer with a new radiolabeled anti-PSMA monoclonal antibody conjugated with IRDye800CW 48
Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging 48
Development of 177Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen 48
Dual-modality image-guided surgery of prostate cancer with a radiolabeled fluorescent anti-PSMA monoclonal antibody 45
Totale 8.201
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.881
article - articoli 22.779
book - libri 0
conference - conferenze 7.064
curatela - curatele 0
other - altro 0
patent - brevetti 556
selected - selezionate 0
volume - volumi 482
Totale 61.762
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020578 0 0 0 0 0 100 94 57 40 93 68 126
2020/2021905 68 145 61 95 113 101 21 66 52 20 97 66
2021/2022884 79 250 14 81 37 18 16 51 20 33 74 211
2022/20231.892 147 181 171 322 136 457 74 130 200 13 46 15
2023/2024898 43 85 91 94 109 122 35 55 12 79 123 50
2024/2025945 113 153 61 367 169 82 0 0 0 0 0 0
Totale 8.587